logo-loader
viewJ Sainsbury PLC

CMA issues 'invitation to comment' on proposed merger of Sainsbury's and Asda

All interested parties have been asked to submit initial views on the impact the proposed merger of Sainsbury's and Asda could have on competition by June 4

Sainsbury
The CMA is likely to contact companies in markets affected by the proposed merger

The UK competition watchdog has started gathering information into the proposed merger of J Sainsbury plc (LON:SBRY) and Asda ahead of a formal investigation.

Sainsbury’s and Asda, which is owned by Walmart Inc (NYSE:WMT), last month agreed to a £15bn merger to create the UK’s largest supermarket group.

Britain's Competition and Market Authority (CMA) said in a statement on Friday that it has issued a preliminary “invitation to comment” asking all interested parties to submit initial views on the impact the deal could have on competition by June 4.

The regulator said it is also likely to contact companies in markets affected by the proposed merger, or that have "valuable insights or evidence that could assist the CMA's investigation, such as suppliers, competitors, industry bodies and consumer organisations”.

“The CMA is keen to ensure that all interested parties have the opportunity to make their views known and present all relevant evidence to the CMA,” it said.

It is also looking to send out a consumer survey to hear customers' thoughts about the deal. 

Some analysts have said they expect the two supermarkets will be asked to sell stores to get the go-ahead from the CMA. 

READ: Sainsbury's and Asda may have to sell at least 73 supermarkets, research shows

David Haywood, founder of Maximise UK – a specialist in identifying new locations for retail stores – believes at least 6% or 73 of the enlarged group’s supermarkets are at risk, excluding convenience stores.

Quick facts: J Sainsbury PLC

Price: 204.8 GBX

LSE:SBRY
Market: LSE
Market Cap: £4.53 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

1 day, 14 hours ago

RNS

Adjustment of Conversion Price

2 days, 22 hours ago

Adjustment of Conversion Price

2 days, 22 hours ago

Half-year Report

1 week, 3 days ago

Total Voting Rights

2 weeks, 2 days ago

Director/PDMR Shareholding

2 weeks, 2 days ago

Directorate Changes

2 weeks, 4 days ago

2 min read